ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases

ConserV Bioscience and eTheRNA immunotherapies…

ONA Therapeutics appoints Mark Throsby to its Board of Directors

ONA Therapeutics appoints Mark Throsby…

Novadip Biosciences receives IND approval from the FDA for regenerative bone product NVD-003

Novadip Biosciences receives IND approval…

Immunic, Inc. Announces Positive Top-Line Data From Investigator- Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

Immunic, Inc. Announces Positive Top-Line…

Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

Immunic, Inc. Announces That Oral…

Minoryx Therapeutics in the news

Minoryx Therapeutics in the news

Minoryx presents topline results from Phase 2/3 “ADVANCE” study demonstrating significant clinical benefit of leriglitazone in adrenomyeloneuropathy (AMN)

Minoryx presents topline results from…

Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich´s ataxia

Minoryx’s clinical candidate leriglitazone shows…

Immunic, Inc. Added to NASDAQ Biotechnology Index

Immunic, Inc. Added to NASDAQ…

eTheRNA and China Grand Pharma enter a strategic collaboration in the Greater China Region focussed on eTheRNA’s proprietary mRNA development products and manufacturing capabilities

eTheRNA and China Grand Pharma…